Close

XBiotech (XBIT) Says Results from Phase 2 Clinical Trial of Bermekimab in Treatment of Atopic Dermatitis to be Presented at ADD

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. IBM
4. HCP
5. PI
6. LRCX
7. BIIB
8. F
9. CNMD
10. BSX


Go back to XBiotech (XBIT) Says Results from Phase 2 Clinical Trial of Bermekimab in Treatment of Atopic Dermatitis to be Presented at ADD

Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting

March 1, 2019 11:45 AM EST

Rapid and significant reduction in skin lesions, 66% (p... More